… SD were imputed using interquartile ranges (dividing the range by 1.35 [ 25 ]) and full ranges
(dividing the range by values from Pearson’s table [ 26 ]). Change-from-baseline SD were …

… e ) and the coefficient of selection (s). If s is much greater than 1/2N e , as would be expected
in large populations, selection will be the dominant factor, while if s≪1/2N e the mutations …

… ’s transport emissions are expected to be more than double by 2035. This would significantly
worsen the country’s … ways to reduce the country’s GHG emissions from the transport sector. …

… R&D intensity, confirming the conclusions of Srholec’s study. … Turen [5] follow Tebaldi’s model
with data from 15 European … or weaker depending on country’s specialisation in high-tech …

Background Prostate cancer is a heterogeneous disease, but current treatments are not based
on molecular stratification. We hypothesized that metastatic, castration-resistant prostate …

Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …

… Potential modifications included the drug(s) included in the criterion, the recommendation,
the rationale, the quality of evidence, and the strength of recommendation. As noted in the …

The 2015 American Geriatrics Society ( AGS ) Beers Criteria are presented. Like the 2012
AGS Beers Criteria, they include lists of potentially inappropriate medications to be avoided in …

Background Enzalutamide, an androgen-receptor inhibitor, has been associated with improved
overall survival in men with castration-resistant prostate cancer. It is not known whether …

… alteration in prespecified genes with a direct or indirect role in homologous recombination
repair were randomly assigned to receive the PARP inhibitor olaparib or the physician’s …